0001860010-23-000004.txt : 20230609 0001860010-23-000004.hdr.sgml : 20230609 20230609190015 ACCESSION NUMBER: 0001860010-23-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230609 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ORTH ANDREW C. CENTRAL INDEX KEY: 0001860010 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38210 FILM NUMBER: 231006751 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Krystal Biotech, Inc. CENTRAL INDEX KEY: 0001711279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 821080209 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 BUSINESS PHONE: (412) 586-5830 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 4 1 wk-form4_1686351600.xml FORM 4 X0407 4 2023-06-09 0 0001711279 Krystal Biotech, Inc. KRYS 0001860010 ORTH ANDREW C. C/O KRYSTAL BIOTECH, INC. 2100 WHARTON STREET, SUITE 701 PITTSBURGH PA 15203 0 1 0 0 Chief Commercial Officer 1 Common Stock 2023-06-09 4 M 0 12500 63.55 A 12600 D Common Stock 2023-06-09 4 S 0 5261 128.1045 D 7339 D Common Stock 2023-06-09 4 S 0 6906 128.9441 D 433 D Common Stock 2023-06-09 4 S 0 333 129.6972 D 100 D Stock Option (Right to Buy) 63.55 2023-06-09 2023-06-09 4 M 0 12500 0 D 2032-02-27 Common Stock 12500 37500 D The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share. The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023. /s/ Andrew Orth 2023-06-09